In this issue:
Long-term sequelae in childhood leukaemia survivors with Down syndrome
Escalated BEACOPP in Hodgkin lymphoma with positive PET after two ABVD cycles
Kinetics and nadir of response to anti-PD1 in Hodgkin lymphoma
Venetoclax with decitabine or azacitidine in elderly patients with previously untreated AML
Inotuzumab ozogamicin + low-intensity chemo for older patients with Ph-negative ALL
Brentuximab vedotin + bendamustine in R/R Hodgkin lymphoma
Gene expression and cytogenetics predict resistance to AML induction
DLBCL outcomes independent of Epstein-Barr virus positivity or immunosuppression
Romidepsin and pralatrexate in R/R T-cell lymphoma
Mutation patterns identify elderly patients with AML who respond to chemo
Please login below to download this issue (PDF)